Skip to main content
10 articles related to "Ceftolozanetazobactam"

Articles

Original Research

Published on 17 Apr 2025

Ceftolozane/tazobactam use and emergence of resistance: a 4-year analysis of antimicrobial susceptibility in Pseudomonas aeruginosa isolates in a tertiary hospital

in Antimicrobials, Resistance and Chemotherapy

  • Alessandra Imeneo
  • Laura Campogiani
  • Pietro Vitale
  • Andrea Di Lorenzo
  • Grazia Alessio
  • Davide Natale Abate
  • Maria Grazia Celeste
  • Anna Altieri
  • Cartesio D’Agostini
  • Vincenzo Malagnino
Frontiers in Microbiology
doi 10.3389/fmicb.2025.1542491
  • 3,263 views
  • 3 citations

Original Research

Published on 05 Jun 2024

Ceftazidime/avibactam resistance is associated with PER-3-producing ST309 lineage in Chilean clinical isolates of non-carbapenemase producing Pseudomonas aeruginosa

in Antibiotic Resistance and New Antimicrobial drugs

  • Katherine D. Soto
  • Manuel Alcalde-Rico
  • Juan A. Ugalde
  • Jorge Olivares-Pacheco
  • Valeria Quiroz
  • Bárbara Brito
  • Lina M. Rivas
  • José M. Munita
  • Patricia C. García
  • Aniela Wozniak
Frontiers in Cellular and Infection Microbiology
doi 10.3389/fcimb.2024.1410834
  • 4,508 views
  • 3 citations

Original Research

Published on 13 Feb 2024

Extensively drug-resistant Pseudomonas aeruginosa: clinical features and treatment with ceftazidime/avibactam and ceftolozane/tazobactam in a tertiary care university hospital center in Portugal – A cross-sectional and retrospective observational study

in Antimicrobials, Resistance and Chemotherapy

  • Diogo Mendes Pedro
  • Sérgio Eduardo Paulo
  • Carla Mimoso Santos
  • Ana Bruschy Fonseca
  • José Melo Cristino
  • Álvaro Ayres Pereira
  • Cátia Caneiras
Frontiers in Microbiology
doi 10.3389/fmicb.2024.1347521
  • 8,409 views
  • 16 citations

Original Research

Published on 03 Oct 2022

Role of the multi-drug efflux systems on the baseline susceptibility to ceftazidime/avibactam and ceftolozane/tazobactam in clinical isolates of non-carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

in Experimental Pharmacology and Drug Discovery

  • María José Contreras-Gómez
  • José R. W. Martinez
  • Lina Rivas
  • Roberto Riquelme-Neira
  • Juan A. Ugalde
  • Aniela Wozniak
  • Patricia García
  • José M. Munita
  • Jorge Olivares-Pacheco
  • Manuel Alcalde-Rico
Frontiers in Pharmacology
doi 10.3389/fphar.2022.1007162
  • 6,544 views
  • 6 citations